John Parkinson

New information suggests a few more cases have surfaced in the United States, pending CDC confirmation.

A team of investigators studied Clostridioides difficile infection (CDI) isolates to gauge resistance in the 2 antibiotics.

The company issued the voluntary action due to potential salmonella contamination concerns.

Companies say the 3 doses of their vaccine meet all immunobridging criteria required for the Emergency Use Authorization (EUA).

A health system piloted a program that explored having an infectious disease pharmacist aid in guiding treatment.

Investigators sought information on how the infection is treated in outpatient clinics

A study looked at the utilization of the technology with this antibiotic class in hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP).

AdventHealth Orlando studied a small number of these fungal isolates to examine treatment resistance patterns.

Tend, a startup company, has developed its Gut Microbiome Collect and Prep (CAP) to enable a standardized method for stool (microbiome) encapsulation for the procedure.

The company is utilizing this platform to address new COVID-19 variants, combination vaccines, and potentially prevent HIV.

Tetracycline-class antibiotic, omadacycline (Nuzyra), is FDA approved for community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI), and is also being studied for other potential indications.

The company's investigational vaccine, which is in a phase 3 study, is an example of its commitment to addressing these viruses.

The organization has its upcoming antimicrobial stewardship meeting in less than two weeks, and offers professional education and training in infectious diseases with a special emphasis on antimicrobial stewardship.

The federal agency revised the vaccine’s Emergency Use Authorization after an analysis of the risk for thrombosis with thrombocytopenia syndrome (TTS).

These behind-the-scenes, essential personnel remain a significant part of health care and is a field with growth opportunities, but remain a field in need of public awareness to enable its stability.

If authorized, this would be the first vaccine applicable to the youngest pediatric group.

These paramount medical personnel behind the scenes are facing staffing challenges that could be bordering on a national crisis in public health.

The filing included data from their phase 2/3 trial in this pediatric age group.

The supplemental new drug application is expanded to include the youngest COVID-19 patients.

The cases are in the pediatric population and come from 11 countries in the WHO European Region and 1 country in the WHO Region of the Americas.

Although the development of antibiotics remains a challenge, there are some legislative strategies that could make it more attractive and get more players involved.

A group of over 60 scientists participated in a communication to the federal agency to advocate for measuring these cells in COVID-19 vaccine trials.

The investigational vaccine's findings from their phase 1/2 clinical trial were reported at the World Vaccine Congress.

With an evolving understanding of T-cells in immunity and emerging SARS-Co-V2 strains, evaluating these vital protection cells can offer researchers insights into response and how to develop future therapies and vaccines.

The company says its first bivalent investigational vaccine, mRNA-1273.211, was efficacious against the Beta, Delta, and Omicron strains. They have identified another bivalent booster, mRNA-1273.214, which the company sees as its leading candidate for a fall 2022 scheduled dosing.

Masking requirements on public transportation was struck down by a federal judge late yesterday, which is leading to confusion for travelers today.

The InspectIR COVID-19 Breathalyzer test detects chemical compounds in breath samples associated with a SARS-CoV-2 infection.

The 36-fold increase in Omicron neutralizing titers in children between 5-11 years old is providing data for the companies to be able to file for an FDA EUA in this age group.

The investigational shots utilizing their mRNA technology platform are being studied in adults in the US.

A survey’s results show updating programs is largely dependent on resources and dedicated personnel.